Last updated on August 2018

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients with Dementia, Including Alzheimer’s Disease


Brief description of study

To take part, your loved one must:

 be at least 55 years of age,

 be diagnosed with probable Alzheimer’s disease,

 be showing behaviors of agitation associated with Alzheimer’s,

 have a friend or loved one that can take part in the study with them.

Clinical Study Identifier: TX209898

Find a site near you

Start Over

Parker Jewish Institute

271-11 76th Ave New Hyde Park, NY USA
  Connect »